MX2020011007A - Derivado de péptido-1 (glp-1) similar al glucagón acilado. - Google Patents

Derivado de péptido-1 (glp-1) similar al glucagón acilado.

Info

Publication number
MX2020011007A
MX2020011007A MX2020011007A MX2020011007A MX2020011007A MX 2020011007 A MX2020011007 A MX 2020011007A MX 2020011007 A MX2020011007 A MX 2020011007A MX 2020011007 A MX2020011007 A MX 2020011007A MX 2020011007 A MX2020011007 A MX 2020011007A
Authority
MX
Mexico
Prior art keywords
derivative
acylated glp
glp
drug
acylated
Prior art date
Application number
MX2020011007A
Other languages
English (en)
Inventor
Feng Li
Zheng Xu
Rui Song
Wanjun Guo
Hai Pan
Zhaosheng Lin
Jianhui Deng
Jing Feng
Original Assignee
Sciwind Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciwind Biosciences Co Ltd filed Critical Sciwind Biosciences Co Ltd
Publication of MX2020011007A publication Critical patent/MX2020011007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan un análogo de polipéptido GLP-1 (7-37), un derivado modificado con ácido graso del análogo y un medicamento que comprende el derivado; además, también se proporciona un método de preparación del derivado y el uso del mismo en la preparación de un medicamento.
MX2020011007A 2018-04-19 2019-04-19 Derivado de péptido-1 (glp-1) similar al glucagón acilado. MX2020011007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2018/083789 WO2019200594A1 (zh) 2018-04-19 2018-04-19 酰化的glp-1衍生物
PCT/CN2019/083383 WO2019201328A1 (zh) 2018-04-19 2019-04-19 酰化的glp-1衍生物

Publications (1)

Publication Number Publication Date
MX2020011007A true MX2020011007A (es) 2021-01-20

Family

ID=68239398

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011007A MX2020011007A (es) 2018-04-19 2019-04-19 Derivado de péptido-1 (glp-1) similar al glucagón acilado.

Country Status (9)

Country Link
US (2) US11612640B2 (es)
EP (1) EP3783014A4 (es)
JP (2) JP7164247B2 (es)
KR (2) KR102653113B1 (es)
AU (2) AU2019256245B2 (es)
BR (1) BR112020021245A8 (es)
CA (2) CA3135910C (es)
MX (1) MX2020011007A (es)
WO (2) WO2019200594A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022008139A (es) * 2019-12-30 2022-10-03 Gan & Lee Pharmaceuticals Co Ltd Compuestos de glp-1 de acción prolongada.
US20230234916A1 (en) 2020-05-29 2023-07-27 Sciwind Biosciences Co., Ltd. N-[8-(2-hydroxybenzoyl)amino]potassium octanoate crystal polymorph, and preparation method therefor and use thereof
WO2023151594A1 (en) * 2022-02-11 2023-08-17 Hangzhou Sciwind Biosciences Co., Ltd. A composition comprising gip receptor agonists and glp-1 receptor agonists and use thereof
CN115536739B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法
CN115786426B (zh) * 2022-10-31 2023-09-08 杭州先为达生物科技有限公司 高特异性肠激酶酶切方法及乙醇在提高肠激酶酶切特异性中的用途
CN117229346A (zh) * 2022-12-06 2023-12-15 杭州先为达生物科技股份有限公司 一种多肽衍生物及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US692464A (en) 1901-05-04 1902-02-04 Daniel Mackenzie Combined baby carriage and sleigh.
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5424686A (en) 1994-04-20 1995-06-13 Philips Electronics North America Corporation Negative-resistance-compensated microwave buffer
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
PL192359B1 (pl) 1996-08-30 2006-10-31 Novo Nordisk As Pochodna GLP-1(7-37) lub analogu GLP-1(7-37), środek farmaceutyczny oraz zastosowanie pochodnej GLP-1(7-37) lub analogu GLP-1(7-37)
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO2000034331A2 (en) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
KR20020002480A (ko) 1999-03-17 2002-01-09 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 펩티드의 아실화법 및 신규한 아실화제
WO2000069911A1 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
JP2003523366A (ja) 2000-01-27 2003-08-05 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド１化合物の可溶化方法
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
WO2005023291A2 (en) * 2003-09-11 2005-03-17 Novo Nordisk A/S Use of glp1-agonists in the treatment of patients with type i diabetes
KR101243648B1 (ko) * 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
WO2005072045A2 (en) 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
CN1938334A (zh) * 2004-01-30 2007-03-28 瓦拉塔药品公司 Glp－1激动剂和胃泌素化合物的联合使用
US20090117102A1 (en) * 2004-07-01 2009-05-07 Antonio Cruz Methods and compositions using CD3 agonists
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
TW200843794A (en) 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CN101342365A (zh) 2008-08-28 2009-01-14 中国药科大学 一类新型胰高血糖素样肽-1(glp-1)类似物的用途
CN101367873B (zh) 2008-10-08 2011-05-04 南开大学 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
CN104411322B (zh) * 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物
EP2846823B1 (en) * 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
CA2916311A1 (en) 2013-07-04 2015-01-08 Novo Nordisk A/S Derivatives of glp-1 like peptides, and uses thereof
WO2015022400A1 (en) 2013-08-15 2015-02-19 Novo Nordisk A/S Glp-1 derivatives, and uses thereof
WO2015155151A1 (en) * 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
EP3226906B1 (en) 2014-11-27 2019-06-12 Novo Nordisk A/S Glp-1 derivatives and uses thereof
US10392428B2 (en) 2014-12-17 2019-08-27 Novo Nordisk A/S GLP-1 derivatives and uses thereof
CN107033234B (zh) * 2017-01-03 2018-06-26 北京凯因科技股份有限公司 酰化的glp-1衍生物

Also Published As

Publication number Publication date
EP3783014A9 (en) 2021-05-19
US20230330189A1 (en) 2023-10-19
AU2021204749B2 (en) 2022-03-31
CA3135910A1 (en) 2019-10-24
EP3783014A1 (en) 2021-02-24
AU2019256245B2 (en) 2021-08-05
JP2022191398A (ja) 2022-12-27
BR112020021245A8 (pt) 2022-05-10
AU2019256245A1 (en) 2020-11-19
KR20220035996A (ko) 2022-03-22
BR112020021245A2 (pt) 2021-02-02
JP2021522318A (ja) 2021-08-30
CA3202015A1 (en) 2019-10-24
US20210393744A1 (en) 2021-12-23
AU2021204749A1 (en) 2021-07-29
EP3783014A4 (en) 2021-07-07
JP7164247B2 (ja) 2022-11-01
CA3135910C (en) 2023-08-22
JP7499305B2 (ja) 2024-06-13
KR102464605B1 (ko) 2022-11-10
KR20210005093A (ko) 2021-01-13
WO2019201328A1 (zh) 2019-10-24
KR102653113B1 (ko) 2024-04-02
WO2019200594A1 (zh) 2019-10-24
US11612640B2 (en) 2023-03-28

Similar Documents

Publication Publication Date Title
MX2020011007A (es) Derivado de péptido-1 (glp-1) similar al glucagón acilado.
ZA202102696B (en) Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
EP3620474A4 (en) HUMAN FIBROBLAST GROWTH FACTOR 21 (HFGF21) FUSION PROTEIN, METHOD OF MANUFACTURING IT AND USES THEREOF
EP4053160A4 (en) HUMAN COLLAGEN-17 POLYPEPTIDE, METHOD FOR THE PRODUCTION THEREOF AND ITS USE
EP3673869A4 (en) DELIVERY DEVICE FOR SELF-EXPANDING PROSTHESIS AND DELIVERY DEVICE FOR SELF-EXPANDING HEART VALVE PROSTHESIS
EP3569596A4 (en) 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PROCESS OF PREPARATION AND USE IN MEDICINE
MX2023008382A (es) Microcompartimento celular y metodos de preparacion.
WO2017040335A3 (en) Transfection complexes and methods of using the same
EP3474805A4 (en) BACK SUPPORT APPARATUS, CHAIR AND METHOD USING IT
MX2020005170A (es) Formulaciones de proteinas de fusion vegfr-fc.
HUE065354T2 (hu) Kompozit anód aktív anyag, eljárás annak elõállítására, és az azt tartalmazó anód
GB202202474D0 (en) Bioengineered formulation, process for preparing and implementations thereof
EP3805385A4 (en) LENTIVIRAL VECTOR AND METHOD FOR DELIVERY OF EXOGENOUS RNA BY THE LENTIVIRAL VECTOR
EP4063363A4 (en) PYRAZOLE HETEROARYL DERIVATIVE, PROCESS THEREOF AND MEDICAL USE THEREOF
EP3650448A4 (en) INDOLE-FORMAMIDE, PROCESS OF PREPARATION AND USE IN MEDICINE
EP3874992A4 (en) DETACHABLE CHAIR BASE AND CHAIR
EP3838925A4 (en) LONG-ACTING GLP1-FC-CD47 RECOMBINANT PROTEIN, METHOD FOR PREPARATION AND USE
WO2020068196A3 (en) Proteins that inhibit cas12a (cpf1), a crispr-cas nuclease
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
EP3960849A4 (en) ALLOGENEIC CAR-T CELLS, THEIR PRODUCTION AND USE
EP3760191A4 (en) PHARMACEUTICAL COMPOSITION, PROCESS FOR PREPARATION AND USE OF THE LATTER
EP3939615A4 (en) MANUFACTURING PROCESS AND USE FOR AN ARTIFICIAL EXOCRINE COMPLEX
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
EP3266801A4 (en) Human interferon-beta variant conjugated immunocytokine and method for preparing same
MX2022007945A (es) Formulacion compleja que comprende sitagliptina y dapagliflozina, y metodo de preparacion de la misma.